Posterior scleritis with anti-neutrophil cytoplasmic antibody-associated vasculitis utilizing rituximab therapy to maintain remission: A case report

Xinyu Weng, Daiju Iwata, Kenichi Namba, Kayo Suzuki, Kazuomi Mizuuchi, Hiroyuki Nakamura, Tatsuya Atsumi, Susumu Ishida

Abstract

Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a necrotizing vasculitis syndrome characterized by the destruction of small vessels, leading to various organ disorders. Here, we report a case of posterior scleritis with AAV successfully treated with prednisolone and rituximab (RTX) combination therapy.

Observations: A 69-year-old female suffered from ocular pain and redness in her left eye for 2.5 years. She had been diagnosed with idiopathic otitis media before a year. At her initial visit, scleral injection with nodular elevated scleral lesions, vitreous haze, and serous retinal detachment (SRD) in the inferior periphery were observed in the left eye. Enhanced computed tomography revealed the enhancement and thickening of the left sclera. The results of laboratory analysis were positive for myeloperoxidase ANCA. Accordingly, she was diagnosed with AAV. Owing to the exacerbation of vitreous haze and SRD, topical treatment and steroid pulse therapy were initiated. Following therapy, anterior and posterior scleritis improved, and additional RTX was administered to maintain the remission. Following treatment, the patient has maintained remission with 10 mg/day prednisolone to date.

Conclusions and importance: We encountered a case of posterior scleritis with AAV in which inflammatory manifestations subsided with RTX and glucocorticoid combination therapy. RTX administration likely contributed to the maintenance of remission.

1. Introduction

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a necrotizing vasculitis syndrome characterized by the destruction of small vessels, leading to the dysfunction of various organs, such as the ear, nose, throat, eye, respiratory tract, kidney, skin, and nervous system. Typical ocular complications include scleritis, episcleritis, orbital inflammation, lacrimal duct stenosis, and uveitis. Rituximab (RTX) is a chimeric monoclonal antibody against B-cell-specific CD20. RTX has recently been recommended for the treatment of granulomatosis with polyangiitis (GPA) in patients who are resistant to or intolerant of cyclophosphamide (CYC).
Betamethasone for two months. There was no improvement, and she was thus referred to our hospital. She had been diagnosed with otitis media of unknown etiology before a year, and her family history was unremarkable.

At her initial visit to our hospital, the best-corrected visual acuity (BCVA) was 0.9 in the right eye (OD) and 0.7 OS. Intraocular pressure was within the normal range in both eyes. Slit-lamp examination showed the injection of the sclera and conjunctiva, 1+ flare, 1+ cells of anterior chamber inflammation with fine keratic precipitates, and nodular-elevated lesion in the upper sclera OS (Fig. 1). Fundus examination revealed 1+ vitreous haze, a yellowish elevated lesion at the superotemporal periphery, and serous retinal detachment (SRD) at the inferotemporal periphery OS (Fig. 2a). Optical coherence tomography (OCT) revealed cystoid macular edema and retinal pigment epithelium (RPE) undulations OS (Fig. 2b). There were no abnormal findings, except mild superficial punctate keratopathy OD. Ultrasound biomicroscopy revealed enlargement of the supraciliary space OS (Fig. 2c), and B-mode ultrasonography revealed the thickening and flattening of the posterior coats OS (Fig. 2d).

Laboratory analysis revealed high titers of antinuclear antibody (ANA) (1:160) and the CRP level was as high as 0.4 mg/dl. The results were positive for myeloperoxidase ANCA (MPO-ANCA) and negative for proteinase 3 ANCA (PR3-ANCA) (Table 1). Others results were not significant.

Computed tomography (CT) revealed high brightness of the soft tissue enhanced by the contrast agent in the left orbit and inferior retinal detachment OS (Fig. 3a–b). Magnetic resonance imaging (MRI) revealed enlargement of the supraciliary space and retinal detachment OS (Fig. 4).

This patient was diagnosed with AAV in consultation with a rheumatologist and categorized as GPA on the basis of the Watts classification. She was treated with topical betamethasone for three weeks after her initial visit. However, BCVA decreased to 0.15 and anterior chamber inflammation and vitreous haze OS exacerbated. OCT revealed the aggravation of SRD and RPE undulations OS. Therefore, she was treated with steroid pulse therapy, and her ocular findings improved (Fig. 5). Three weeks after the treatment, RTX was additionally administered at a dose of 500 mg/week for 4 weeks to maintain the remission. As the injection of the sclera and conjunctiva, vitreous haze, and SRD were resolved, PSL dose was gradually tapered. However, 3 months after the initial treatment when the PSL dose was tapered to 12.5 mg/day, SRD...
was observed in the macula OS (Fig. 6). Therefore, PSL dose was increased to 30 mg/day along with the administration of azathioprine and subtenon injection of 40 mg of triamcinolone acetonide OS. In response to these additional treatments, SRD disappeared OS. Fourteen months after the initial treatment, BCVA increased to 0.5 OS. Although focal thinning and vasodilatation of the sclera persisted (Fig. 7a) and epiretinal membrane developed (Fig. 7b and c), the scleral injection, peripheral yellowish lesions, and SRD disappeared OS. No recurrence has been noted to date, and the patient is currently receiving 10 mg/day of PSL.

3. Discussion

Posterior scleritis accounts for 2–12% of all scleritis cases,6 and it often requires aggressive therapy7 because of vision-threatening complications including vitritis, macular edema, and exudative retinal detachment.8 Scleritis associated with systemic diseases, such as rheumatoid arthritis, recurrent polychondritis, and AAV, is often refractory to treatment. The incidence of scleritis associated with such
autoimmune diseases has been reported to be approximately 20–40%. In a previous study, 66% cases of scleritis associated with systemic diseases were refractory and only 6% were mild. AAV can be categorized into three distinct forms, namely GPA (previously known as Wegener’s granulomatosis), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (previously known as Churg-Strauss syndrome).

In the present case, although MPO-ANCA was positive, the patient presented no history of allergic diseases, pulmonary and renal abnormalities, or eosinophilia. Moreover, she presented with symptoms such as eye pain, vision loss, otitis media, and episcleritis.

Watts and colleagues proposed an AAV classification algorithm. This stepwise algorithm incorporated both the American College of Rheumatology (ACR) criteria for EGPA and GPA and the Chapel Hill Consensus Conference (CHCC) definition of EGPA, GPA, and MPA. In this case, she was diagnosed with AAV in consultation with a rheumatologist. According to the Watts classification, her AAV was categorized into GPA based on the findings of otitis media, posterior scleritis, and MPO-ANCA positivity.

Glucocorticoids (GCs) and immunosuppressants were the gold standard for AAV treatment. Although a combination therapy of a GC and an immunosuppressant is effective in the majority of GPA patients, the 2-year relapse rate of GPA is approximately 18–40%. In Japan, the combination therapy of CYC and GCs has been a gold standard to achieve remission in AAV. However, the frequency of treatment-associated side effects, such as infectious complications, cardiovascular diseases, myelosuppression, malignancy, and infertility, remains high.

RTX is a cytotoxic monoclonal antibody, which depletes B cells upon CD20 binding. The efficacy of RTX against non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis has been proven, and this drug is now anticipated to be approved for the treatment of other chronic inflammatory conditions. Moreover, RTX has been used to maintain remission in AAV since 2001. In 2011, the European League Against Rheumatism recommended RTX and GC combination therapy as the initial management of GPA. In Japan, RTX was approved for GPA treatment in 2013.

In the present case of AAV associated with posterior scleritis, considering the risk of rapid vision loss, RTX and GC combination therapy was administered after consulting a collagen vascular disease specialist. The RTX treatment was considered effective, and the patient successfully maintained remission with a low dose of PSL, although she exhibited mild recurrence once.

The risk of impairment of visual function is much higher in posterior scleritis than anterior scleritis. Therefore, inducing and maintaining the remission is required more in posterior scleritis. Recillas-Gispert et al. and You et al. exhibited the case series of GPA patients with scleritis and revealed the effectiveness of RTX therapy, in which posterior scleritis was involved only one of 8 and one of 9 cases, respectively.

The present case is a rare case report of posterior scleritis associated with AAV providing the detail of clinical course and indicating the benefit of RTX in the management of posterior scleritis associated with AAV.

Based on the present case, RTX may contribute to the maintenance of remission. In addition, taking the various adverse effects of GCs into account, the trend of immune regulation is shifting toward minimizing their use and preferring RTX application. Nonetheless, the detailed mechanism of action of RTX in AAV remains unknown and warrants further research.

4. Conclusion

We encountered a case of posterior scleritis associated with MPO-ANCA-positive AAV, in which inflammatory manifestations subsided following RTX and PSL combination therapy. RTX administration likely contributed to the maintenance of remission in this case.

Patient consent

Institutional review board approval was not required for this case report of a single patient. Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. This report does not contain any personal information that could reveal the patient’s identify.

Funding

No funding or grant support.

Authorship

All authors attest that they meet the current ICMJE criteria for Authorship.

Authors’ contributions

Xinyu Weng: Data curation, Writing- Original draft preparation, Daiju Iwata: Conceptualization, Writing- Reviewing and Editing, Kenichi Nambo: Conceptualization, Supervision., Writing- Reviewing and Editing, Kayo Suzuki: Data curation, Kazuomi Mizuuchi: Data curation, Hiroyuki Nakamura: Supervision. Tatsuya Atsumi: Supervision. Susumu Ishida: Supervision.
Fig. 5. Clinical course Three weeks after the initial visit, methylprednisolone (mPSL) pulse therapy (1g/day × 3) was initiated, followed by rituximab (0.5g/week × 4) administration. Three months after the treatment, when serous retinal detachment (SRD) appeared in the macular area, prednisolone (PSL) dose was increased along with the administration of oral azathioprine and subtenon triamcinolone acetonide (STTA) (40mg). In response to these treatments, SRD disappeared, and the remission has been maintained to date.

Fig. 6. Optical coherence tomographic scan of the left eye three months after the initial treatment
Serous retinal detachment in the macula of the left eye was observed.
Fig. 7. Ocular findings of the left eye 14 months after the initial treatment. a. Slit-lamp photographs: Focal thinning of the sclera and remaining scleral vasodilatation were observed. b. Fundus examination: Elevated lesions and serous retinal detachment (SRD) disappeared. c. Optical coherence tomography: SRD in the macula disappeared, and the epiretinal membrane developed.

Declaration of competing interest

The following authors have no financial disclosures: (XW, DI, KN, KS, KM, HN, TA, SI).

Acknowledgements

None.

References

1. Isobe M, Amano K, Arimura Y, et al. Guidelines for Management of Vasculitis Syndrome. 2017:1–109.
2. Patompong U, Cynthia SC, Rodrigo CC, et al. Clinical characteristics of inflammatory ocular disease in anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study. Rheumatology. 2017 Oct;56(10):1763–1770.
3. Yates M, Watts R. ANCA-associated vasculitis. Clin Med. 2017 Feb;17(1):60–64.
4. Ozaki S, Makino H, Matsu S, et al. ANCA-related Vasculitis Medical Treatment Guideline. 2011:1–105.
5. Richard W, Suzanne L, Thomas H, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007 Feb;66(2):222–227.
6. Benson WE. Posterior scleritis. Surv Ophthalmol. Mar-Apr 1988;32(5):297–316.
7. Keino H, Watanabe T, Taki W, et al. Clinical features and visual outcomes of Japanese patients with scleritis. Br J Ophthalmol. 2010 Nov;94(11):1459–1463.
8. Jabs DA, Mudun A, Dunn JP, et al. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000 Oct;130(4):469–476.
9. Rajii VR, Palestine AG, Farver DL. Scleritis and systemic disease association in a community-based referral practice. Am J Ophthalmol. 2009;148(6):946–950.
10. Wieringa WG, Wieringa JE, Ten Dam-van Loon NH, et al. Visual outcome, treatment results, and prognostic factors in patients with scleritis. Ophthalmology. 2013;120(2):379–386.
11. Akpek EK, Thorne JE, Ozari FA, Do DV, Jabs DA. Evaluation of patients with scleritis for systemic disease. Ophthalmology. 2004 Mar;111(3):501–506.
12. Bernauer W, Pleisch B, Brunner M. Five-year outcome in immune-mediated scleritis. Graefe’s Arch Clin Exp Ophthalmol. 2014;252(9):1477–1481.
13. Mukhtyar C, Guillevin L, Cid MC, et al. European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009 Mar;68(3):310–317.
14. Arimura Y, Maruyama S, Homma S, et al. Clinical Practice Guideline for ANCA-Associated Vasculitis. 2017:1–46.
15. Specks U, Merkel PA, See F, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417–427.
16. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–232.
17. Letziel H, Lukas C, Barnetche T, Gujoujous-Vialia C, Conbe B, Morel J. Efficacy and safety of biological DMARDs modulating B cells in primary Sjogren syndrome: systematic review and meta-analysis. Joint Bone Spine. Joint Bone Spine. 2018 Jan;85(1):15–22.
18. Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50.
19. Randall KL. Rituximab in autoimmune diseases. Aust Prescr. 2016 Aug;39(4):131–134.
20. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583–1594.
21. Recillas-Gispert C, Serna-Ojeda JC, Flores-Suarez LF, et al. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener’s). Graefe Arch Clin Exp Ophthalmol. 2015;253:2279–2284.
22. You C, Ma L, Lasave AF, et al. Rituximab induction and maintenance treatment in patients with scleritis and granulomatosis with polyangiitis (Wegener’s). Oral Immunol Inflamm. 2018;26(8):1166–1173.
23. Smith RM. Update on the management of ANCA-associated vasculitis. Presse Med. 2015 Jun;44(6 Pt 2):e241–249.